India, April 8 -- Biocon Pharma, a subsidiary of Biocon, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Dapagliflozin Tablets, 5 mg and 10 mg.The approved product is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.This approval further strengthens Biocon's expanding diabetes portfolio, which spans oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides, reinforcing the Company's integrated approach to add...